---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: OASISplus"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: OASISplus. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 36 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence/oasisplus"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: OASISplus

<a id="heading-3.1.5"></a>

## 3.1.5 OASISplus

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Open-label extension cohort objective

> “The majority of patients enrolled in OASIS-HAE (83/90, 92.2%) rolled over into the open-label extension (OLE) cohort of the ongoing OASISplus study (NCT05392114), which is designed to evaluate the long-term safety and efficacy of donidalorsen treatment.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.1-2"></a>

#### Switch cohort objective

> “The Switch cohort of the OASISplus study (NCT05392114) evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Registered study dates and enrollment status

| Field | Reported value |
| --- | --- |
| Study start | “2022-07-13” |
| Primary completion, estimated | “2026-12” |
| Study completion, estimated | “2027-03” |
| Recruitment status | “Active, not recruiting” |

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

<a id="topic-3.1.5.2-2"></a>

#### Data cutoff for the year 1 analyses

> “This prespecified analysis of the ongoing OASISplus study reports results for patients who completed the OLE through Week 52 (including 28 additional days of follow-up, defined as the on-treatment period) as of a January 27, 2025 data cut.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

> “OASISplus is an ongoing, global, open‐label study designed to evaluate the long‐term safety and efficacy of donidalorsen 80 mg administered SC in patients with HAE‐C1INH‐Type1 and HAE‐C1INH‐Type2”
> “(data cutoff date: January 27, 2025)”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Open-label, single-group design with two cohorts

> “An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

> “OASISplus is an ongoing multicenter, phase 3 study composed of 2 cohorts: a de novo cohort of patients who switched from prior LTPs to donidalorsen 80 mg Q4W (Switch cohort), and an OLE cohort of patients who rolled over from the OASIS-HAE study.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Open-label extension cohort: rollover from OASIS-HAE

> “Patients were eligible to enroll in the OLE if they successfully completed the OASIS-HAE study or if they had five or more attacks/month for two consecutive months after Week 4 of OASIS-HAE, in which case they could rollover early into the OLE and receive donidalorsen Q4W”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.4-2"></a>

#### Switch cohort: age and stable prior prophylaxis

> “Participants must be aged ≥ 12 years at the time of informed consent and, as applicable, assent.”
> “Participants must be on a stable dose (≥ 12 weeks) of prophylaxis treatment with lanadelumab or berotralstat or SC C1-esterase inhibitor prior to the Screening Period.”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

> “the Switch cohort included adults and adolescents aged ≥ 12 years on stable prophylactic doses of plasma‐derived or recombinant C1INH via SC or intravenous (IV) administration, lanadelumab, or berotralstat.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.4-3"></a>

#### Switch cohort: exclusions for concomitant medicines and prior oligonucleotides

> “Participated in a prior donidalorsen study.”
> “Angiotensin-converting enzyme (ACE) inhibitors or any estrogen containing medications with systemic absorption.”
> “Oligonucleotides (including small interfering ribonucleic acid”
> “within 4 months of Screening if single dose received, or within 12 months of Screening if multiple doses received.”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Open-label extension cohort: assignment to every-4-week or every-8-week dosing

> “Patients who received donidalorsen 80 mg or placebo Q4W in OASIS-HAE received donidalorsen 80 mg Q4W in OASISplus.”
> “Patients who received donidalorsen 80 mg or placebo Q8W in OASIS-HAE received donidalorsen 80 mg Q8W in OASISplus, unless they were not attack-free during the last 8 weeks (Weeks 16–24) in OASIS-HAE, in which case they received donidalorsen Q4W in OASISplus.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.5-2"></a>

#### Switch cohort: transition algorithm from prior prophylaxis

> “patients were switched from their prior LTP administered during the baseline period to donidalorsen 80 mg administered SC Q4W with no washout period using a prespecified algorithm that was designed to minimize HAE attacks during the switching process”
> “Patients who received prior lanadelumab received their last dose 14 ± 3 days prior to the first dose of donidalorsen on Day 1 of the study, and patients who received prior berotralstat or C1INH continued the treatment for 14 ± 3 days after Day 1 of the study.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.5-3"></a>

#### Planned treatment duration

> “Group 1 and Group 2 participants will be administered donidalorsen by SC injection for up to 157 weeks.”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Treatment-emergent Adverse Event Incidence as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Primary endpoint: incidence and severity of treatment-emergent adverse events

> “Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity”

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

> “The primary endpoint was the incidence of TEAEs, as defined by the Medical Dictionary for Regulatory Activities System Organ Class, and TEAE severity.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

> “The primary endpoint was the incidence and severity of treatment‐emergent adverse events (TEAEs) and their relation to donidalorsen treatment.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.6.1-2"></a>

##### Secondary endpoints: attack rate and angioedema quality of life

> “Rates of HAE attacks were time-normalized per every 4-week period (28 days), also termed monthly.”
> “AE-QoL is a validated, 17-item, disease-specific, self-administered questionnaire with four domains calculated using a scale of 0 to 100, with lower scores indicating better QoL, and a minimal clinically important difference of ≥6 points.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.6.1-3"></a>

##### Switch cohort: attack-rate baseline measured on prior prophylaxis

> “Baseline for the HAE attack rate endpoint in this study was the time from the 10‐week screening period to study Day 1, and was Day 1 for all other endpoints.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.6.1-4"></a>

##### Exploratory endpoint: disease control on the Angioedema Control Test

> “Scores of 10 or higher indicate well-controlled disease.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Registered enrollment

| Population | Participants |
| --- | --- |
| Actual enrollment, both cohorts | “154” |

Source: [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

<a id="topic-3.1.5.7.1-2"></a>

##### Open-label extension cohort

> “The OLE cohort included 83 patients (Q4W, n=69 [83%]; Q8W, n=14 [17%]).”
> “No formal sample size calculations were performed”
> “The sample size for the OLE cohort was dictated by the number of patients enrolled in the OASIS-HAE study and their eligibility for the study.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.7.1-3"></a>

##### Switch cohort by prior prophylactic treatment

> “A total of 65 patients were enrolled in the original cohort, and of these, 64 (98.5%) patients received at least one dose of donidalorsen (prior lanadelumab, n = 31; prior berotralstat, n = 11; prior C1INH, n = 22 [SC, n = 15; IV, n = 7])”
> “The Switch cohort sample size was instead determined per clinical assessment.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Open-label extension cohort: safety and full analysis sets

> “results were summarized with descriptive statistics including observed mean, median, patient numbers, and percentages.”
> “All endpoints were analyzed using data from the safety and full analysis sets, both defined as all patients who received at least one dose of donidalorsen.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.7.2-2"></a>

##### Switch cohort: descriptive analysis without a comparator group

> “As OASISplus was an open‐label study in which all patients received donidalorsen, no comparator group and no formal sample size calculations were performed to address group differences.”
> “The safety set was used for the primary outcome and all safety analyses. The efficacy endpoints were summarized using descriptive statistics in the full analysis set.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Open-label extension cohort: completion and discontinuation at year 1

> “As of the data cutoff date (January 27, 2025), 75 patients (90%) completed Week 52 in the OLE study. Eight patients (10%) discontinued treatment early due to voluntary withdrawal (n = 4), AEs (n = 3), or pregnancy (n = 1; Supplemental Table 1).”
> “six patients changed from donidalorsen Q8W in OASIS-HAE to Q4W dosing in OASISplus, and 19 patients from the OASIS-HAE placebo group were assigned to receive donidalorsen Q4W”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.1-2"></a>

##### Switch cohort: completion and discontinuation at year 1

> “54 (83.1%) patients completed 1 year of treatment”
> “A total of 11 (16.9%) patients discontinued donidalorsen treatment, including 8 (12.3%) patients who switched from lanadelumab and 3 (4.6%) patients who switched from SC or IV C1INH.”
> “In patients who received lanadelumab before switching to donidalorsen, the most common reason for treatment discontinuation was lack of efficacy (n = 4)”
> “No patients who received prior berotralstat therapy discontinued treatment.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Open-label extension cohort: demographics and baseline attack rate

| Characteristic, total (N=83) | Reported value |
| --- | --- |
| Age, years, mean (SD) | “37 (14)” |
| Age 12 to 17 years, n (%) | “7 (8.4)” |
| Female, n (%) | “45 (54.2)” |
| White, n (%) | “76 (91.6)” |
| Baseline HAE attack rate, mean (SD) | “3.4 (2.1)” |

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.2-2"></a>

##### Switch cohort: demographics and baseline attack rate on prior prophylaxis

| Characteristic, total (N=64) | Reported value |
| --- | --- |
| Age, years, mean (SD) | “42 (15)” |
| Age 12 to 17 years, n (%) | “4 (6.3)” |
| Female, n (%) | “38 (59.4)” |
| White, n (%) | “57 (89.1)” |
| Baseline HAE attack rate, mean (SD) | “0.9 (1.3)” |

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Open-label extension cohort: reduction in attack rate from OASIS-HAE baseline, weeks 0 to 52

> “The mean reduction in HAE attack rate over the 52-week OLE was 94% (median, 98%) in the Q4W group (including patients who moved from Q8W dosing in OASIS-HAE to Q4W in the OLE) and 95% (median, 96%) in the donidalorsen Q8W group.”
> “This corresponded to a reduction in mean (SD) time-normalized monthly HAE attack rate from 3.5 (2.13) and 2.9 (2.06) at baseline to 0.3 (0.45) and 0.1 (0.10) over Weeks 0 to 52 in the Q4W and Q8W dosing groups, respectively.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.3-2"></a>

##### Open-label extension cohort: attack-free participants, weeks 4 to 52

> “A total of 48% (Q4W) and 29% (Q8W) were attack-free during the same period”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.3-3"></a>

##### Switch cohort: change in attack rate from baseline on prior prophylaxis, weeks 0 to 52

> “Overall, HAE attack rates decreased by 67.6% from a mean (SD) of 0.85 (1.3) at baseline (on their prior HAE prophylactic therapy) to 0.28 (0.4) over the treatment period through 1 year (Weeks 0–52) of the study”
> “Patients who switched from lanadelumab experienced a 63.9% decrease, patients who switched from berotralstat experienced an 83.1% decrease, and patients who switched from C1INH experienced a 50.7% decrease in HAE attack rate from baseline.”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

##### Open-label extension cohort: AE-QoL and disease control at week 52

> “The mean (SD) reduction from baseline in AE-QoL total score at Week 52 was 27.8 (16.1) points overall, 28.1 (15.7) points in the Q4W group, and 26.7 (18.2) points in the Q8W group.”
> “68 of 70 (97%) patients with an AECT evaluation at both OASIS-HAE baseline and OASISplus Week 52 reported well-controlled disease (AECT score ≥10)”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.4-2"></a>

##### Switch cohort: AE-QoL, disease control, and treatment satisfaction at week 52

> “AE‐QoL total score improved by a mean (SD) of 12.2 (17.6) points from baseline to Week 52 in the overall population”
> “Overall, after 52 weeks of treatment with donidalorsen, 90.4% of patients had well‐controlled disease (prior lanadelumab, n/N = 18/22 [81.8%]; prior berotralstat, n/N = 10/10 [100%]; prior C1INH, n/N = 19/20 [95.0%]; Figure 3).”
> “The overall mean (SD) global satisfaction domain score on the TSQM‐II improved from 75.7 (21.5) at baseline to 89.4 (15.3) at Week 52”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Open-label extension cohort: treatment-emergent adverse events at year 1

| Event, total (N=83) | Participants, n (%) |
| --- | --- |
| Any TEAE | “75 (90.4)” |
| TEAE related to study drug | “22 (26.5)” |
| TEAE leading to discontinuation | “3 (3.6)” |
| Any serious TEAE | “7 (8.4)” |

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.5-2"></a>

##### Open-label extension cohort: serious events, liver enzymes, and bleeding

> “Seven (8%) patients, all of whom received donidalorsen Q4W, reported serious AEs; none were considered drug related.”
> “One patient in the Q4W group died by suicide, considered unrelated to treatment.”
> “the other had a 30-day persistence of alanine aminotransferase levels at >5 times the upper limit of normal (ULN) with normal blood bilirubin concentration that resolved after treatment discontinuation.”
> “There were no major bleeding events or treatment-related trends in activated partial thromboplastin time observed during the treatment period.”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.5-3"></a>

##### Open-label extension cohort: hypersensitivity reaction after year 1

> “one patient experienced a serious type 1 hypersensitivity reaction characterized by rash, dyspnea, perioral swelling, and chest pain after receiving the 29th dose of donidalorsen Q4W (being on this regimen for approximately 2.5 years).”

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/)

<a id="topic-3.1.5.8.5-4"></a>

##### Switch cohort: treatment-emergent adverse events at year 1

| Event, total (N=64) | Participants, n (%) |
| --- | --- |
| Any TEAE | “56 (87.5)” |
| TEAE related to study drug | “24 (37.5)” |
| TEAE leading to discontinuation | “1 (1.6)” |
| Any serious TEAE | “1 (1.6)” |

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.8.5-5"></a>

##### Switch cohort: most common treatment-related adverse events

> “The most common treatment‐related AEs occurring in more than 5% of the overall population were injection‐site erythema (10.9%), injection‐site pruritus (10.9%), injection‐site pain (7.8%), and fatigue (7.8%).”

Source: [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/)

<a id="topic-3.1.5.8.5-6"></a>

##### Immunogenicity in the open-label extension

> “In an open-label extension trial, patients that rolled over from OASIS-HAE continued treatment with DAWNZERA in the 80 mg every 4 weeks or every 8 weeks groups for up to 3 years (median exposure duration of 227 days).”
> “The incidence rate of treatment-emergent ADAs was 35% (22 of 63 patients) in the DAWNZERA 80 mg every 4 weeks group”
> “The incidence rate of treatment-emergent ADAs was 21% (3 of 14 patients) among patients who received DAWNZERA 80 mg every 8 weeks in OASIS-HAE and open-label extension.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

OASISplus is an open-label study with no comparator group, and both cohort publications summarized outcomes with descriptive statistics and no formal sample size calculation.

The open-label extension cohort enrolled 83 of the 90 OASIS-HAE participants (69 receiving donidalorsen every 4 weeks and 14 every 8 weeks). Participants continued every-8-week dosing only if they had been attack-free during the last 8 weeks of OASIS-HAE, so the every-8-week group of 14 participants was selected for response. The 94% and 95% reductions are measured from the OASIS-HAE baseline, before any prophylaxis in that trial.

The Switch cohort dosed 64 participants who had been receiving lanadelumab (31), berotralstat (11), or C1 inhibitor (22). Its attack-rate baseline was the screening period on the prior prophylactic treatment (mean 0.85 attacks per month), so the 67.6% reduction is a within-participant comparison with continued prior prophylaxis, without randomization or blinding. Eleven participants (16.9%) discontinued during the first year, including 4 who had switched from lanadelumab and discontinued for lack of efficacy. The subgroups by prior therapy contain 11 to 31 participants, which limits precision for comparisons between them.

In both cohorts, 89.1% to 91.6% of participants were White. The registry lists an actual enrollment of 154 participants across the study, and the two cohort publications report 83 and 65 participants enrolled. The year 1 publications report data through January 27, 2025, and the registry lists treatment for up to 157 weeks, with primary completion estimated for December 2026.

Source: [Lumry et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948764/); [Riedl et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466153/); [ClinicalTrials.gov NCT05392114](https://clinicaltrials.gov/study/NCT05392114)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
